Operational EfficiencyThe company plans to streamline the organization, reducing its workforce to extend its operating runway into 4Q25, indicating improved financial sustainability.
Product PipelinePreliminary dose-escalation results for GBM remain on track and progress with COVID-19 and flu Phase 2 trials continues, showing promise in CureVac's pipeline.
Strategic PartnershipsCollaboration with MD Anderson for antigen discovery and vaccine development, with CureVac retaining exclusive rights, enhances the company's research capabilities.